MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00296-016-3649-2

Медицинская библиотека · Rheumatology international · 2017

Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis.

Sung Yoon-Kyoung, Cho Soo-Kyung, Kim Dam, Choi Chan-Bum, Won Soyoung, Bang So-Young, Cha Hoon-Suk, Choe Jung-Yoon, Chung Won Tae, Hong Seung-Jae, Jun Jae-Bum, Kim Hyoun Ah, Kim Jinseok, Kim Seong-Kyu, Kim Tae-Hwan, Lee Hye-Soon, Lee Jaejoon, Lee Jisoo, Lee Shin-Seok, Lee Sung Won, Lee Yeon-Ah, Nah Seong-Su, Suh Chang-Hee, Yoo Dae-Hyun, Yoon Bo Young, Bae Sang Cheol, BIOPSY and KORONA investigators

Сравнительное исследованиеСтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод в очереди

Аннотация

OBJECTIVE

To compare the clinical effectiveness of two treatment strategies for active rheumatoid arthritis (RA) refractory to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs): starting TNF inhibitors (TNFIs) or changing csDMARDs.

METHODS

We used two nationwide Korean RA registries for patient selection. TNFI users were selected from the BIOPSY, which is an inception cohort of RA patients starting biologic DMARDs. As a control group, we selected RA patients with moderate or high disease activity from the KORONA database whose treatment was changed to other csDMARDs. After comparing baseline characteristics between the two groups in either unmatched or propensity score matched cohorts, we compared potential differences in the 1-year remission rate as a primary outcome and changes in HAQ-DI and EQ-5D scores as secondary outcomes.

RESULTS

A total of 356 TNFI starters and 586 csDMARD changers were identified from each registry as unmatched cohorts, and 294 patients were included in the propensity score matched cohort. In the intention-to-treat analysis, TNFI starters had higher 1-year remission rates than csDMARD changers in both unmatched (19.1 vs. 18.4%, p < 0.01) and matched cohorts (19.7 vs. 15.0%, p < 0.01). In per protocol analysis, TNFI starters had much higher remission rates in unmatched (37.2 vs. 28.0%, p = 0.04) and matched cohorts (35.4 vs. 19.1%, p = 0.04). However, in matched cohorts, no significant differences were observed between two groups in HAQ-DI and EQ-5D scores.

CONCLUSIONS

We compared the clinical effectiveness of the two treatment strategies for active RA refractory to csDMARDs. TNFI starters showed higher 1-year remission rates than csDMARD changers.

Для цитирования: Sung Yoon-Kyoung, Cho Soo-Kyung, Kim Dam, Choi Chan-Bum, Won Soyoung, Bang So-Young, Cha Hoon-Suk, Choe Jung-Yoon, Chung Won Tae, Hong Seung-Jae, Jun Jae-Bum, Kim Hyoun Ah, Kim Jinseok, Kim Seong-Kyu, Kim Tae-Hwan, Lee Hye-Soon, Lee Jaejoon, Lee Jisoo, Lee Shin-Seok, Lee Sung Won, Lee Yeon-Ah, Nah Seong-Su, Suh Chang-Hee, Yoo Dae-Hyun, Yoon Bo Young, Bae Sang Cheol, BIOPSY and KORONA investigators. Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis.. Rheumatology international. 2017. DOI: 10.1007/s00296-016-3649-2.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.